Philip Morris International enters the first week of June with a notable split in its signals: the Street is turning more constructive at the top, while options traders have pushed put demand to its highest level of the past year — a rare divergence for a defensive income name trading at $173.66.
The most striking move came directly from Morgan Stanley. Eric Serotta raised his price target on PM to $200 from $190 on June 3, maintaining an Overweight rating — a reversal from April, when the same analyst had trimmed his target to $190 from $205 amid broader tariff-driven uncertainty. The timing matters. The stock pulled back 4.3% over the past week despite a mild 0.6% bounce on Tuesday, and the upgrade arrives as PM still trades roughly 13% below the consensus mean target of $193.86. The consensus read across the Street is broadly positive, with multiple Buy-rated firms — Needham at $200, Stifel at $195, Citi at $210 — all sitting above the current price. Only UBS holds a dissenting Neutral view, with a $168 target implying the stock is fairly valued near these levels.
Options positioning tells a more cautious story. The put/call ratio has climbed to 1.16, just a hair below Tuesday's reading of 1.16 — the highest level of the past 52 weeks — and the z-score of 1.83 signals that demand for downside protection is running nearly two standard deviations above the 20-day average of 1.10. For a stock that typically attracts yield-focused, low-volatility buyers, this degree of put accumulation is unusual. It suggests a subset of holders is hedging into Q2 results, scheduled for July 22, rather than trimming outright.
Short interest is low and not the story here. PM's short interest runs at just 1.09% of free float — essentially unchanged over the week and still within the narrow 1.05%–1.15% band that has defined the past six weeks. Borrowing shares is trivially cheap at 0.43% annualised cost, up roughly 28% on the week in percentage terms but still a fraction of anything that would suggest meaningful short conviction. Borrow availability is entirely loose; there is no squeeze dynamic, no lending tightness, and nothing in the borrow market to animate the short side.
The bull case rests on the smoke-free transition. IQOS and Zyn volume growth has the potential to outpace Street estimates, and the 2022 Swedish Match acquisition deepens the nicotine pouch exposure just as that category accelerates. The ORTEX stock score sits at 79, near a six-month high, with quality the standout pillar — a Piotroski F-Score of 7, a 15% return on assets, and a 22% free cash flow margin. EPS momentum scores in the 58th percentile, with forward estimates drifting modestly higher over both 30- and 90-day windows. The bear case is more structural: combustible volumes are declining roughly 3% per year, an upcoming Japanese excise tax increase pressures IQOS margins, and the 5–7% organic revenue growth target for 2026 is already below the company's own prior guidance. The EV/EBITDA multiple at 16x has compressed slightly over 30 days, but the trailing PE of roughly 20x leaves little room for miss.
Institutional ownership is stable and heavily indexed. Capital Research holds 18.5% of shares, with BlackRock and Vanguard each near 6.5%. JP Morgan Asset Management added over 7.2 million shares in the last reported period — the largest increment among the top 15 holders — a meaningful move that reflects active positioning rather than passive drift. Insider activity peaked in mid-February, when CEO Jacek Olczak sold 80,000 shares near $182 and the CFO sold 33,800 shares at similar levels. Those sales came with the stock at a premium to today's price; no purchases appear in the recent record.
With Q2 results seven weeks out, the setup to watch is whether the options hedging — unusually elevated for a defensive Tobacco name — gets confirmed or unravelled by any fresh guidance commentary or by the macro backdrop for smoke-free volume trends in the US and Japan.
See the live data behind this article on ORTEX.
Open PM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
